A
Akari Therapeutics
Developing bi-functional antibody drug conjugates for cancer
About Akari Therapeutics
Akari Therapeutics plc is a biotechnology company that has transitioned its focus to oncology, specifically developing next-generation bi-functional antibody-drug conjugates (ADCs) for cancer treatment. This strategic shift followed a merger with Peak Bio, Inc., which was completed in November 2024. The merger expanded Akari's pipeline to include an innovative ADC discovery platform, novel payloads, and linker technologies.
The company was originally founded as Celsus Therapeutics in 2004 and focused on autoimmune and inflammatory diseases. A key figure in its history is Dr. Ray Prudo, who founded Volution Immuno Pharmaceuticals in 2008 and joined Akari in September 2015 when Volution merged with Celsus. Over the years, the company has undergone several leadership changes. In March 2022, Rachelle Jacques was appointed President and CEO, succeeding Clive Richardson. Jacques stepped down in May 2024, and Samir Patel, a board member since December 2023, took over as interim CEO. Following the Peak Bio merger, Dr. Hoyoung Huh, the founder and Chairman of Peak Bio, became the Chairman of Akari's board. In April 2025, Abizer Gaslightwala, a seasoned biotechnology executive with over 25 years of experience, was appointed the new President and CEO.
Akari's lead ADC candidate is AKTX-101, which targets the TROP2 receptor found on various solid tumors. It delivers a proprietary, first-in-class payload called PH1, a spliceosome modulator designed to disrupt RNA splicing in cancer cells. This mechanism aims to induce tumor-specific cell death and generate an immune response, potentially overcoming limitations of existing ADCs like off-target toxicity and resistance. Before its pivot to oncology, Akari's lead asset was nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) for autoimmune and inflammatory diseases, which had reached Phase 3 trials for conditions like pediatric HSCT-TMA. The company is also developing a long-acting version, PAS-nomacopan, for geographic atrophy (GA).
As a publicly traded company on the Nasdaq (AKTX), Akari's business model is centered on the research and development of its therapeutic candidates. Its revenue generation will depend on the successful clinical development, regulatory approval, and subsequent commercialization or partnership of its pipeline assets. The company has secured financing through private placements and has an equity line of credit to fund its operations and development milestones.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
News
Open roles
Akari Therapeutics in the Walton-on-Thames ecosystem
The Akari Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
NEA
Foresite Capital
Venrock
Vivo Capital
RA Capital Management
Deerfield- DPDr. Ray Prudo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Akari Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Akari Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


